Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine, S-ketamine, and R-ketamine for treatment-resistant major depressive disorder
ChiCTR1800015879Phase 2Not yet recruiting
- Sponsor
- Wuxi Mental Health Center
- Start
- Jul 2018
- Modality
- Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in major depressive disorder (MDD) comparing Ketamine group, Esketamine group and Arketamine group (3 arms). Primary endpoint: Hamilton Depression Rating Scale. Planned start Jul 2018; status: not yet recruiting.
02
Drugs
ketamineesketaminer-ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ChiCTR1800015879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800015879.